Mycophenolate mofetil in lupus nephritis

Lupus

Volumn 14, Issue 1, 2005, Pages 59-64

  Ginzler, Ellen M ^a,c   Aranow, C ^b  

^a SUNY Downstate Medical Center   (United States)

^b New York Presbyterian Hospital Columbia University Medical Center   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Lupus nephritis; Mycophenolate mofetil; SLE

Indexed keywords

AZATHIOPRINE; CELL ADHESION MOLECULE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CORTICOSTEROID; CREATININE; CRYOGLOBULIN; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; DNA ANTIBODY; DOUBLE STRANDED DNA; GUANOSINE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NUCLEOTIDE; PREDNISOLONE; PREDNISONE; TETRAHYDROBIOPTERIN; THROMBOXANE A2;

ALOPECIA; AMENORRHEA; ANTIBODY PRODUCTION; ANTIBODY TITER; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; GRAFT REJECTION; HUMAN; INFECTION; KIDNEY BIOPSY; KIDNEY FUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTOPENIA; NAUSEA; NONHUMAN; PANCREATITIS; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; REVIEW; SEROLOGY; STOMATITIS; SURVIVAL;

ANIMALS; CLINICAL TRIALS; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MICE; MODELS, ANIMAL; MYCOPHENOLIC ACID; TREATMENT OUTCOME;

EID: 13444263407     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203305lu2061oa     Document Type: Review

References (30)

1. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
2. Corna D, Morigi M, Facchinetti D, Bertani T, Zoja C, Remuzzi G. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int 1997; 51: 1583-1589.
3. McMurray RW, Elboume KB, Lagoo A, Lal S. Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB × NZW F1 mouse model of systemic lupus erythematosus. J Rheumatol 1998; 25: 2364-2370.
4. Ramos MA, Pinera C, Setien MA et al. Modulation of autoantibody production by mycophenolate mofetil: effects on (NZB × NZW) F1 mice. Nephrol Dial Transplant 2003; 18: 878-883.
5. Zoja C, Benigni A, Noris M et al. Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. Kidney Int 2001; 60: 653-663.
6. van Bruggen MC, Walgreen B, Rijke TP, Berden JH. Attenuation of murine lupus nephritis by mycophenolate mofetil. J Am Soc Nephrol 1998; 9: 1407-1415.
7. Jonsson CA, Svensson L, Carlsten H. Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice. Clin Exp Immunol 1999; 116: 534-541.
8. Yu CC, Yang CW, Wu MS et al. Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice. J Lab Clin Med 2001; 138: 69-77.
9. Lui SL, Tsang R, Wong D et al. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/ lpr mice. Lupus 2002; 11: 411-418.
10. Glicklich D, Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am 3 Kidney Dis 1998; 32: 318-322.
11. Gaubitz M, Schorat A, Schotte H, Kern P, Domschke W. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 1999; 8: 731-736.
12. Dooley MA, Cosio FG, Nachman PH et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999; 10: 833-839.
13. Li L-S, Hu W-X, Zhou H, Liu Z-H. Clinico-pathological evaluation of mycophenolate mofetil (MMF) therapy in twenty-three cases of diffuse proliferative lupus nephritis (SLE-DPGN). JAm Soc Nephrol 1999; 10: 172 (abstract 0881).
14. Kingdon EJ, McLean AG, Psimenou E et al. The safety and efficacy of MMF in lupus nephritis: A pilot study. Lupus 2001; 10: 606-611.
15. Karim MY, Alba P, Cuadrado MJ et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology 2002; 41: 876-882.
16. Riskalla MM, Somers EC, Fatica RA, McCune WJ. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 1508-1512.
17. Kapitsinou PP, Boletis JN, Skopouli FN, Boki KA, Moutsopoulos HM Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology 2004; 43: 377-380.
18. Ferro ML, Karim MY, Abbs IC, D'Cruz DP, Khamashta MA, Hughes GRV Mycophenolate mofetil: a potential treatment for reducing proteinuria associated with membranous lupus nephritis. Arthritis Rheum 2003; 48: S588.
19. Fu YF, Liu GL. Mycophenolate mofetil therapy for children with lupus nephritis refractory to both intravenous cyclophosphamide and cyclosporine. Clin Nephrol 2001; 55: 318-321.
20. Buratti S, Szer IS, Spencer CH, Bartosh S, Reiff A. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 2001; 28: 2103-2108.
21. Bijl M, Horst G, Bootsma H, Limburg PC, Kallenberg CGM. Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann Rheum Dis 2003; 62: 534-539.
22. Chan TM, Li FK, Tang CSO et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. New Engl J Med 2000; 343: 1156-1162.
23. Falk RJ. Treatment of lupus nephritis - a work in progress. New Engl J Med 2000; 343: 1182-1183.
24. Chan TM, Wong RWS, Lau CS et al. Prolonged follow-up of patients with diffuse proliferative lupus nephritis treated with prednisolone and mycophenolate mofetil. J Am Soc Nephrol 2001; 12: 195A (abstract).
25. Ye Z, Tan YH, Hong XP, Feng XX, Xiao XL. MMF vs CTX in the treatment of severe SLE patients. Lupus 2001; 10: S99 (abstract, suppl. 1).
26. Hu W, Liu Z, Chen H et al. Mycophenolate Mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J 2002; 115: 705-709.
27. Ginzler EM, Aranow C, Buyon J et al. A multicenter study of mycophenolate mofetil (MMF) vs. intravenous cyclophosphamide (IVC) as induction therapy for severe lupus nephritis (LN): preliminary results. Arthritis Rheum 2003; 48: S647.
28. Ginzler EM, Aranow C, Merrill JT, Orloff K, Henry D. Toxicity and tolerability of mycophenolate mofetil (MMF) vs. intravenous cyclophosphamide (TVC) in a multicenter trial as induction therapy for lupus nephritis (LN). Arthritis Rheum 2003; 48: S586.
29. Naylan JF. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. Transplantation 1997; 64: 1277-1282.
30. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-980.